Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial



Summary

A correction was issued regarding the phase 2 SWOG S1512 trial, which investigated anti-PD-1 therapy (pembrolizumab) for unresectable desmoplastic melanoma. The correction addressed errors in the initial publication, primarily affecting data presentation and minor statistical calculations. While the updated analysis refined the initial findings, the overall conclusions regarding the efficacy of pembrolizumab in this specific melanoma subtype remain consistent: anti-PD-1 therapy demonstrates clinically meaningful activity, offering a promising treatment option for patients with unresectable desmoplastic melanoma. The corrections ensure the accuracy and reliability of the reported data.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!